



PATENT APPLICATION

1653

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on March 29, 2002.


Stephen A. Slusher, Reg. No. 43,924

March 29, 2002
(Date Signed)

gms p#3

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APR 05 2002

TECH CENTER 1600/2900

Applicant(s): Christine H. Blood,
Annette M. Shadiack, Joanna K. Bernstein,
and Guy W. Herbert

Examiner: UNKNOWN

Serial No.: 10/040,547

RECEIVED

Filed: January 4, 2002

Group Art Unit: 1653

APR 05 2002

For: COMPOSITIONS AND METHODS FOR
TREATMENT OF SEXUAL DYSFUNCTION

TECH CENTER 1600/2900

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE
MONTHS OF FILING OR BEFORE MAILING OF FIRST OFFICE ACTION
(37 CFR § 1.97(b))

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office Action on the merits, whichever event occurs last. 37 CFR § 1.97(b).

Dated: March 29, 2002

By: 

Stephen A. Slusher
Reg. No. 43,924
Direct line: (505) 998-6130

Attorneys for Applicant(s)
PEACOCK, MYERS & ADAMS, P.C.
P.O. BOX 26927
Albuquerque, New Mexico 87125-6927
Telephone: (505) 998-1500
Facsimile: (505) 243-2542

+

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

(use as many sheets as necessary)

1

of

10/040,547

January 4, 2002

BLOOD, Christine H.

1653

70025-04-CIP

70025-04-CIP

~~RECEIVED~~

[illegible]

~~TECH CENTER 1600/2900~~

[illegible]

**Examiner
Signature**

Date	
Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Trademark, DC 20231.**

Please type a plus sign (+) inside this box

+

PTO/SB/08B (10-96)


Approved for use through 10-31-99. OMB 0651-003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no

persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		COMPLETE IF KNOWN	
		Application Number	10/040,547
		Filing Date	January 4, 2002
		First Named Inventor	BLOOD, Christine
		Group Art Unit	1653
		Examiner Name	
Sheet 1 of 1	Attorney Docket Number	70025-APR 04 2 2002 CIP	



RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
		Bednarek M.A. et al., "Structure-function studies on the cyclic peptide MT-II, lactam derivative of α -melanotropin," <i>Peptides</i> , Vol. 20:401-09 (1999)	
		Hadley M.E. et al., "Melanocortin Receptors: Identification and Characterization by Melanotropic Peptide Agonists and Antagonists," <i>Pigment Cell Res.</i> , Vol. 9:213-34 (1996)	
		Haskell-Luevano C. et al., "Discovery of Prototype Peptidomimetic Agonists at the Human Melanocortin Receptors MC1R and MC4R," <i>Journal of Medical Chemistry</i> , Vol. 40:2133-39 (1997)	
		Hruby, V.J., et al., "Cyclic Lactam α -melanocyte-stimulating Hormone-(4-10)-NH ₂ with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors," <i>Journal of Medicinal Chemistry</i> , Vol. 38, No. 18: 3454-61 (1995)	
		Schiöth H.B. et al., "Discovery of novel melanocortin ₄ receptor selective MSH analogues," <i>British Journal of Pharmacology</i> , Vol. 124:75-82 (1998)	
		Schiöth H.B. et al., "Selective properties of C- and N-terminals and core residues of the melanocyte-stimulating hormone on binding to the human melanocortin receptor subtypes," <i>European Journal of Pharmacology</i> , Vol. 349:359-66 (1998)	
		Wessells H. et al., "Synthetic Melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study," <i>Journal of Urology</i> , Vol. 160:389-393 (1998)	
		<u>Metabolism of Brain Peptides</u> , Ed. G. O'Cuinn, CRC Press, New York, 1995, pp. 1-9 and 99-101	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[F:\MIKE\PATENT\IDS\Palatin\Sex Dysfunction 1449form-2-2.pat.doc]

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.